Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.

Shih-Hao HuangAllen Chung-Cheng HuangChin-Chou WangWen-Chen ChangChien-Ying LiuStelios PavlidisHo-Wen KoFu-Tsai ChungPing-Chih HsuYi-Ke GuoAllen Chung-Cheng HuangCheng-Ta Yang

Published in: Thoracic cancer (2019)

Ceritinib showed higher efficacy associated with a better control of systemic progression compared to crizotinib for the front-line treatment of ALK-positive advanced NSCLCs.

Keyphrases

advanced non small cell lung cancer
small cell lung cancer
diffuse large b cell lymphoma
drug induced
smoking cessation
replacement therapy